Wane

New Study Published in The American Journal of Pathology Suggests Obeticholic Acid (OCA) May Improve Cognitive Impairment Associated with Cholestatic Liver Disease

MORRISTOWN, N.J., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics ...
MedPage Today

FDA Reviewers Skeptical of Ocaliva for Rare Bile Duct Disease

FDA advisors on Friday will be asked to find any clinical benefit in the rocky, mostly-null evidence for obeticholic acid (Ocaliva) in primary biliary cholangitis (PBC). In its present supplemental ...
MedPage Today

FDA Issues Safety Alert on Liver Disease Drug

Postmarketing data on obeticholic acid (Ocaliva) identified a risk for serious liver injury in primary biliary cholangitis (PBC) patients without cirrhosis, the FDA said in a safety communication on ...
Healio

Patients with PBC who failed with obeticholic acid may still achieve ‘some benefit’

Please provide your email address to receive an email when new articles are posted on . Incomplete responders to obeticholic acid had significant increases from baseline in fibroblast growth factor 19 ...
Medscape

Non-Response to Obeticholic Acid May Predict Clinical Outcomes in Primary Biliary Cholangitis

Biochemical non-response to obeticholic acid as a second-line therapy predicted a heightened risk for clinical events in patients with primary biliary cholangitis (PBC). Although response rates to ...
Healio

VIDEO: Livdelzi may fill therapeutic gap in PBC for patients previously receiving OCA

Please provide your email address to receive an email when new articles are posted on . “We did this study following the announcement of the withdrawal of obeticholic acid for PBC treatment in the U.S ...